• Home
  • Pharmacy Medical Policy Updates

Pharmacy Medical Policy Updates

The following Pharmacy Medical Policy programs have been updated Feb. 1, 2023:

Effective March 1, 2023:

  • Camzyos
  • Long Acting Insulin
  • Human Fibrinogen Concentrate
  • IL-4 Inhibitor
  • IL-5 Inhibitors
  • Lysosomal Storage Disorders
  • Relyvrio
  • Spevigo

Many of our pharmacy medical policies are maintained through our pharmacy benefit manager, Prime Therapeutics.

To find pharmacy medical policies specific to a medication list, please select a medication list at the bottom of our prior authorization page of our website, https://www.bcbsks.com/providers/precertification-prior-authorization

If you have any questions regarding this newsletter, please contact your BCBSKS provider representative/consultant.

Institutional Providers
Professional Providers